NCT04635826 is a Phase 4 clinical trial of Adderall 10Mg Tablet in Prescription Stimulants, sponsored by University of Alabama at Birmingham.

Who is sponsoring NCT04635826?

NCT04635826 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT04635826?

Interventions in NCT04635826: Adderall 10Mg Tablet, Placebo.

What condition does NCT04635826 study?

NCT04635826 studies Prescription Stimulants, Expectations, Deception.

Is NCT04635826 still recruiting?

NCT04635826 is currently withdrawn. Last updated 7 April 2025.

Last reviewed 2025-04-07 · How we verify

NCT04635826

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Role of Expectancy for Cognitive Enhancement in College Students Using Prescription Stimulants Nonmedically

Withdrawn Phase 4 Last updated 7 April 2025

What this trial tests

Phase 4 trial testing Adderall 10Mg Tablet in Prescription Stimulants. Withdrawn.

Timeline

1 July 2025

Primary endpoint
31 July 2029

31 July 2030

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	double
Primary purpose	health services research
Start date	1 July 2025
Primary completion	31 July 2029
Estimated completion	31 July 2030

Drugs / interventions tested

Adderall 10Mg Tablet — full drug profile →
Placebo

Conditions studied

Prescription Stimulants — all drugs for Prescription Stimulants →
Expectations — all drugs for Expectations →
Deception — all drugs for Deception →

Sponsor

University of Alabama at Birmingham

Who can join

Adults 18 to 30, any sex, with Prescription Stimulants or Expectations. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We propose to evaluate the interaction between expectations of receiving stimulants, neurophysiological activity and enhancement of cognitive performance using fMRI.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04635826 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 7 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04635826.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing